問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chi Mei Hospital, Liouying (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

Chi Mei Medical Center (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

Chi Mei Medical Center

更新時間：2023-09-19

高婉真
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

119Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

高婉真

Chi Mei Hospital, Liouying

Division of Hematology & Oncology

List

99Cases

2020-12-01 - 2024-01-30

Phase II

Completed
Phase 2 Study Investigating Efficacy and Safety of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody BGB-A1217 in Patients With Previously Treated Recurrent or Metastatic Cervical Cancer

  • Condition/Disease

    Recurrent or Metastatic Cervical Cancer

  • Test Drug

    BGB-A317 、BGB-A1217

Participate Sites
6Sites

Recruiting6Sites

2020-07-20 - 2029-05-26

Phase III

Active
A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

  • Condition/Disease

    Myelofibrosis (MF)

  • Test Drug

    Navitoclax

Participate Sites
8Sites

Not yet recruiting4Sites

Recruiting4Sites

2020-08-01 - 2028-09-30

Phase III

Completed
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1)

  • Condition/Disease

    Myelofibrosis (MF)

  • Test Drug

    Navitoclax

Participate Sites
6Sites

Not yet recruiting4Sites

Recruiting2Sites

2024-04-29 - 2027-03-01

Phase II

Active
Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors (The HARMONIC Study)

  • Condition/Disease

    Adenocarcinoma of Lung 、Carcinoma, Non-Small-Cell Lung

  • Test Drug

    溶液劑

Participate Sites
5Sites

Recruiting5Sites

2021-12-30 - 2025-12-31

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-11-13 - 2026-12-31

Phase I

Active
A Phase I Study to Evaluate the Safety and Efficacy of RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer

  • Condition/Disease

    Pancreatic Cancer

  • Test Drug

    凍晶注射劑

Participate Sites
2Sites

Recruiting2Sites

2018-06-01 - 2026-08-31

Phase III

Active
A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation

  • Condition/Disease

    Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation

  • Test Drug

    Nivolumab

Participate Sites
12Sites

Recruiting1Sites

Terminated10Sites

林錫銘
Linkou Chang Gung Medical Foundation

Digestive System Department

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

2023-12-15 - 2024-12-06

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting1Sites

Terminated3Sites

2017-07-18 - 2026-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-11-01 - 2030-09-30

Phase I

Not yet recruiting
A Phase 1b/2 Open-Label, Multicenter Study of RMC-9805 with or without RMC-6236, in Combination with Other Anticancer Agents, in Patients with RAS G12D-Mutated Non-Small Cell Lung Cancer (NSCLC) – Subprotocol C

  • Condition/Disease

    RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC) – Subprotocol D

  • Test Drug

    tablets

Participate Sites
5Sites

Not yet recruiting5Sites

1 2 3 4 5 10
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB